文献速递淋巴瘤造血干细胞移植与细胞治疗

霍奇金淋巴瘤患者在接受移植后环磷酰胺的单倍体移植前使用检查点抑制剂

Checkpoint inhibition before haploidentical transplantation with posttransplant cyclophosphamide in Hodgkin lymphoma.
PubMed 文献 · Blood Adv · 2020-01-01

报告59例接受移植后环磷酰胺预防移植物抗宿主病的单倍体造血干细胞移植的霍奇金淋巴瘤患者,按移植前是否暴露于检查点抑制剂分组比较结局。中位随访26个月,CPI组2年无进展生存期独立保护(HR 0.32),疾病稳定/进展是总生存期和无进展生存期的独立不良预后因素。

要点

  • 移植前CPI暴露是PFS的独立保护因素(HR 0.32,P=0.037)。
  • CPI组与无CPI组2年复发累积发生率0 vs 20%(P=0.054)。
  • 疾病稳定/进展是OS和PFS的独立负向预后因素(HR分别为14.3和14.1,P<0.001)。

核心结论

  • 检查点抑制剂作为单倍体移植的桥接似乎改善无进展生存期,且未影响毒性特征。

研究设计与样本

  • 对59例接受移植后环磷酰胺预防移植物抗宿主病的单倍体造血干细胞移植的霍奇金淋巴瘤患者进行报告,按移植前检查点抑制剂暴露分组比较结局。
  • 检查点抑制剂组29例,无检查点抑制剂组30例;两组除既往治疗线数(6 vs 4;P<0.001)外移植前特征相似。
  • 中位随访26个月(范围7.5-55个月)。

主要发现

  • 100天2-4级急性移植物抗宿主病累积发生率在检查点抑制剂组为41%,无检查点抑制剂组为33%(P=0.456)。
  • 1年中重度慢性移植物抗宿主病累积发生率在检查点抑制剂组为7%,无检查点抑制剂组为8%(P=0.673)。
  • 2年复发累积发生率在检查点抑制剂组为0,无检查点抑制剂组为20%(P=0.054)。
  • 2年总生存率在检查点抑制剂组为77%,无检查点抑制剂组为71%(P=0.599);2年无进展生存率分别为78% vs 53%(P=0.066);2年非复发死亡率分别为15% vs 21%(P=0.578)。
  • 多变量分析中,移植前检查点抑制剂暴露是无进展生存期的独立保护因素(风险比0.32;P=0.037);疾病稳定/进展是总生存期和无进展生存期的独立负向预后因素(风险比14.3;P<0.001和风险比14.1;P<0.001)。

临床怎么用

  • 原文结论认为检查点抑制剂作为单倍体移植的桥接似乎改善无进展生存期,且未影响毒性特征。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

We report on 59 Hodgkin lymphoma patients undergoing haploidentical stem cell transplantation (SCT; haplo-SCT) with posttransplant cyclophosphamide (PTCy) as graft-versus-host disease (GVHD) prophylaxis, comparing outcomes based on pretransplant exposure to checkpoint inhibitors (CPIs). Considering pretransplant characteristics, the 2 cohorts (CPI = 29 patients vs no-CPI = 30 patients) were similar, except for the number of prior lines of therapy (6 vs 4; P < .001). With a median follow-up of 26 months (range, 7.5-55 months), by univariate analysis, the 100-day cumulative incidence of grade 2-4 acute GVHD was 41% in the CPI group vs 33% in the no-CPI group (P = .456), whereas the 1-year cumulative incidence of moderate to severe chronic GVHD was 7% vs 8%, respectively (P = .673). In the CPI cohort, the 2-year cumulative incidence of relapse appeared lower compared with the no-CPI cohort (0 vs 20%; P = .054). No differences were observed in terms of overall survival (OS), progression-free survival (PFS), and nonrelapse mortality (NRM) (at 2 years, 77% vs 71% [P = .599], 78% vs 53% [P = .066], and 15% vs 21% [P = .578], respectively). By multivariable analysis, CPI before SCT was an independent protective factor for PFS (hazard ratio [HR], 0.32; P = .037). Stable disease (SD)/progressive disease (PD) was an independent negative prognostic factor for both OS and PFS (HR, 14.3; P < .001 and HR, 14.1; P < .001, respectively) . In conclusion, CPI as a bridge to haplo-SCT seems to improve PFS, with no impact on toxicity profile.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. De Philippis C, Legrand-Izadifar F, Bramanti S, et al. Checkpoint inhibition before haploidentical transplantation with posttransplant cyclophosphamide in Hodgkin lymphoma. Blood Adv. 2020. PMID: 32227210. doi:10.1182/bloodadvances.2019001336

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。